Purpose. A study was undertaken to determine the risk factors and trends in antimicrobial resistance for enteric fever.
INTRODUCTION
Enteric fever is a febrile illness caused by Salmonella enterica subsp. enterica serovar Typhi and Salmonella enterica subsp. enterica serovar Paratyphi A, B, or C. The global burden of disease caused by S. Typhi is estimated to be around 27 million [1] cases per year and the infection is common in low and medium income countries with an unsafe water supply and poor sanitation facilities [2] .
Between 2006 and 2014, 239 cases of enteric fever were reported on average annually in travellers from England, Wales and Northern Ireland visiting friends and relatives in South Asia and 92 were from London (Jo Freedman, personal communication). The non-specific presentation for enteric fever can delay diagnosis and result in inappropriate treatment [2] . In a recent study of enteric fever in returning travellers from East London, the infection was not considered in the initial differential diagnosis of almost half the cases; a third of the patients were discharged from emergency medicine without a clinical diagnosis and only readmitted when blood cultures became positive [3] . Patients often presented late with infection and some patients were admitted to hospital as late as 74 days following entry to the UK [3] . There is no national guidance for the treatment of enteric fever and risk factors and trends in antimicrobial resistance were investigated to inform management.
METHODS Dataset
The dataset was obtained from the Public Health England (PHE) Travel and Migrant Health Section (TMHS) and comprised cases of typhoid and paratyphoid with positive blood cultures for S. Typhi, S. Paratyphi A or B confirmed by the PHE Salmonella Reference Service (SRS) and epidemiological information from enhanced surveillance. The data was deduplicated; one sample per case with laboratory receipt dates between 1 January 2005 and 31 December 2012 was included. Geographical information for a case was initially assigned using the patient's residence by postcode and, if not available, then the location of the source laboratory was used as a proxy. All patients were classed as London residents.
Laboratory-confirmed cases
Laboratory confirmation, typing and antimicrobial susceptibility testing was undertaken by the SRS of the PHE Gastrointestinal Bacteria Reference Unit (GBRU). Selected key antimicrobials tested included ampicillin, chloramphenicol, nalidixic acid, ciprofloxacin, trimethoprim, cephalexin and sulphonomide. If the isolate was sensitive to cephalexin then it was deduced that it would be sensitive to ceftriaxone. The British Society of Antimicrobial Chemotherapy (BSAC) breakpoint method [4] was utilised for antimicrobial susceptibility testing, where indicated, but some antimicrobials (sulphonamide, trimethoprim, nalidixic acid and cephalexin) did not have defined BSAC breakpoints for treating invasive infection with S. Typhi and S. Paratyphi A and B. For some antibiotics two concentrations were tested. Breakpoints used for ampicillin were 8 . We defined cotrimoxazole resistance as resistance to either trimethoprim or sulphonamide. Multidrug resistance three (MDR3) was defined as resistance to ampicillin, chloramphenicol and cotrimoxazole. Multidrug resistance four (MDR4) was defined as resistance to ampicillin, chloramphenicol, cotrimoxazole and ciprofloxacin. Trend analysis was performed for ciprofloxacin in line with current recommendations [4, 5] .
Enteric fever enhanced surveillance Enhanced surveillance of enteric fever has been conducted in England, Wales and Northern Ireland since May 2006. Laboratory-confirmed cases are interviewed by local authorities or health protection teams using an enhanced surveillance form (containing questions on demographics, symptoms, risk groups, travel and vaccination history, and contact and food history for non-travel-related cases) which is sent to TMHS and reconciled with laboratory reports in a central database. A backwards stepwise multivariable logistic regression analysis was conducted to identify variables significantly and independently related to resistance. Variables with a P-value <0.4 were considered for inclusion in the multivariable analysis. Age, gender and year of infection were included in the model regardless of significance.
Statistical methods
All analysis was undertaken in Stata version 13 (StataCorp) [6] .
RESULTS
Cases of S. Paratyphi A, S. Paratyphi B and S. Typhi and antimicrobial resistance There were 453 patients with S. Paratyphi A, of which 29 (6 %) did not travel abroad, 41 (9 %) had an unknown travel history and one case had no information on antimicrobial resistance; thus 382 patients had isolates for analysis. For 611 patients with S. Typhi isolates, 65 (11 %) did not travel abroad, 49 (8 %) had an unknown travel history and one case had no information on antimicrobial resistance. Thus 496 isolates were available for analysis.
No analysis was undertaken for S. Paratyphi B because of small numbers.
Three hundred and thirty four (87 %) S. Paratyphi A isolates were resistant to nalidixic acid and 335 (88 %) isolates were resistant to ciprofloxacin. For the other antibiotics, there were very low numbers of isolates with antimicrobial resistance and further analysis was not undertaken (ampicillin n=6; sulphonamide n=10; chloramphenicol n=6; trimethoprim n=7; cephalexin n=0).
Just over 80 % (398) of S. Typhi isolates were found to be resistant to nalidixic acid, 395 (80 %) to ciprofloxacin, 131 (26 %) to ampicillin, 131 (26 %) to sulphonamide, 162 (27 %) to chloramphenicol and 137 (28 %) to trimethoprim. None of the S. Typhi isolates were resistant to cephalexin. For S. Paratyphi A isolates, there was a significant difference in antibiotic resistance to nalidixic acid (P=0.026) and ciprofloxacin (P=0.018) over this time period. For S. Typhi isolates, there was no significant difference in antimicrobial resistance to ampicillin (P=0.541), sulphonamide (0.441), trimethoprim (P=0.182) and chloramphenicol (P=0.414) over this time period. There was also no significant difference to MDR3 (P=0.38) and MD4 (P=0.547). However, there was a significant difference in resistance to nalidixic acid (P=0.001) and ciprofloxacin (P<0.0001). Table 1 shows single variable analysis for S. Paratyphi A and S. Typhi for ciprofloxacin. Ciprofloxacin and nalidixic acid results were similar and detailed analysis was undertaken for ciprofloxacin only. There was no association between antimicrobial resistance in S. Typhi and S. Paratyphi A isolates from individuals and those visiting friends and family abroad so this information has not been included in the tables. Travellers visiting India were more likely and travellers to Africa less likely to have both S. Paratyphi A and S. Typhi isolates resistant to ciprofloxacin. Travellers to Asia (other than India, Pakistan and Bangladesh) were also less likely to have S. Typhi isolates resistant to ciprofloxacin. S. Paratyphi A PT1a isolates were less likely to be resistant and S. Typhi PT1, PTE9, UVS isolates were more likely to be resistant than those with other PTs. 
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DISCUSSION
The majority of isolates of S. Typhi in returning travellers were resistant to nalidixic acid and ciprofloxacin; while under a third of these isolates were resistant to ampicillin, sulphonamide, chloramphenicol and trimethoprim. No cephalosporin resistance was found so this continues to be an appropriate empirical choice for treating enteric fever.
Recent reports suggest that trends in multidrug resistance in enteric fever isolates from counties with endemic disease appear to be on the decline in countries such as India and drug resistance to ampicillin, chloramphenicol and cotrimoxazole is rare or absent in S. Paratyphi A [7, 8] . However, Wong et al. [9] describe the H58 clade of S. Typhi as a dominant haplotype associated with drug resistance found in Africa and Asia with repeated spread from Asia to Africa. This H58 haplotype is associated with resistance to ampicillin, chloramphenicol, cotrimoxazole, streptomycin and also with reduced susceptibility to ciprofloxacin. Our findings are similar to the results from a study in East London except that there was no resistance detected to ampicillin in the earlier study [10] .
For S. Paratyphi A, the majority of isolates were resistant to nalidixic acid and ciprofloxacin but lack of resistance has been described to ampicillin, sulphonamide, chloramphenicol, trimethoprim or cephalexin [7] . Strikingly, ciprofloxacin resistance against S. Paratyphi A was associated with travel to India and Bangladesh but not to Africa, which has been recognised amongst London clinicians but is discordant with evidence that a multi-resistant clone with resistance to ciprofloxacin has spread to Africa [9] .
Our findings of an approximately steady level of antimicrobial resistance for amoxicillin, trimethoprim or chloramphenicol between 2005-2012 are similar to the findings of a 14 year study involving returning travellers to the Netherlands which found no significant increase in resistance to these antimicrobials [11] . Additionally, resistance to ciprofloxacin increased in the Dutch findings from 1999 to 2012 from 0 % (0/12) to 64.3 % (18/28) [11] . Sixteen percent of the S. Typhi isolates were also resistant to azithromycin. Our isolates were not tested for susceptibility to azithromycin as it was not consistently used for treatment of infection. However, a study of enteric fever in East London over an 8 year period did not detect azithromycin resistance [10] .
The trend data is particularly useful for London as there is no current national or international guidance on the use of antimicrobials for the treatment of enteric fever. The last guidance from the WHO was published in 2003, but this is not useful in the current climate of increasing antibiotic resistance [12] .
We determined a complex relationship between antimicrobial resistance, visiting certain countries and PTs. There was a difference in the pattern of antimicrobial resistance between Asia and Africa and this may reflect the pattern of use of antimicrobials in these regions or perhaps even the prevalence of different strains in different countries.
The majority of travellers from the UK acquiring enteric fever visit friends and relatives in South Asia and understanding recent trends in antibiotic resistance may help guide empiric treatment for enteric fever. In the UK, ceftriaxone is used for empiric treatment of enteric fever, with azithromycin used for cases of uncomplicated typhoid or patients who can be managed in the community. Ciprofloxacin is used only when guided by the results of antimicrobial susceptibility tests or for empiric treatment of enteric fever for patients returning from Africa and this is demonstrated by the lower risk of antimicrobial resistance in travellers returning from Africa.
One limitation of this study is that the breakpoints used for many antimicrobials are not currently recommended by BSAC and EUCAST and resistance data for azithromycin is not available. Although the recommended cut-off of 0.06 mg l À1 to detect ciprofloxacin resistance was not available for this dataset, this is only one dilution difference from the cut-off used in this study. This is within the limits of accepted laboratory error and unlikely to have significantly underestimated quinolone resistance. By using our definition for cotrimoxazole resistance, we may have over-estimated the resistance as the combination is synergistic. However, this is likely to be small and unlikely to affect the overall findings significantly. The breakpoints were used in conjunction with phage typing to assist laboratory testing. Another limitation is that we do not know the proportion of isolates that are sent to reference laboratories for additional testing.
Travellers visiting India were less likely to have S. Typhi infections that were MDR compared to those not visiting India, which is consistent with the findings of an earlier study in East London [9] . However, unlike the findings of the East London study, we found that travellers to Pakistan and Bangladesh were more likely to have S. Typhi isolates which were MDR when compared to those not visiting these countries; however, this did not persist in the multivariate analysis after adjustment for PT.
Resistance to ampicillin, chloramphenicol and cotrimoxazole has been defined as multidrug resistance in the past [13] ; however, it appears that the definition should include ciprofloxacin as the majority of isolates that were resistant to ampicillin, chloramphenicol and cotrimoxazole were resistant to ciprofloxacin and associated with similar risk factors and PTs.
PTE9Var isolates were more likely to show MDR than other PTs. Clinical risk factors for enteric fever in travellers have been described in a recent review article [14] and are not considered further in this publication.
Phage typing continues to be used for strain characterisation and surveillance in humans, food and food production animals. However, its limitations include subjective interpretation relying on the experience of the laboratory and a lack of applicability for global surveillance [15] . Future work on enteric fever isolates using new techniques, such as multiple locus variable-number tandem repeat analysis, multilocus sequence typing and whole-genome sequencing, will improve our understanding of evolutionary patterns, transcontinental spread, antmicrobial resistance genes and future prescribing of antimicrobials for enteric fever.
Conclusion
The proportion of S. Typhi strains showing resistance to ampicillin, chloramphenicol and cotrimoxazole remained steady for the period 2005-2012. There was a significant increase in the overall trend for ciprofloxacin resistance which increased until 2010 and fell for 2011-2012. S. Paratyphi A isolates were increasingly found to be resistant to ciprofloxacin over this same time frame. Specific PTs were associated with resistance to specific antimicrobials and to specific countries. Ceftriaxone can still be used for the empirical treatment of enteric fever as resistance was not detected in this study.
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